Here is the literal biology: GHK-Cu activates Wnt/beta-catenin signaling to restart dormant follicles, suppresses TGF-beta1 to prevent premature regression, stimulates VEGF for perifollicular blood supply, and protects dermal papilla cells from programmed death (Pickart & Margolina, 2018)
The BELIEVE trial was a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effects of semaglutide, bimagrumab, and their combination over 48 weeks, with a 24-week open-label extension
This free radical-mediated damage is considered as the initial pathogenic event in degeneration of melanocyte in generalized vitiligo and supplementing glutathione, which is a potent antioxidant, in vitiligo patients may prove to have therapeutic effect
doi: 10.1016/s0140-6736(08)61246-5 115 FonsecaVADevriesJHHenryRRDonsmarkMThomsenHFPlutzkyJ